COLLEGIUM PHARMACEUTICAL, INCCOLLEarnings & Financial Report
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Revenue
$159.3M
Gross Profit
$96.8M
Operating Profit
$34.8M
Net Profit
$9.3M
Gross Margin
60.8%
Operating Margin
21.9%
Net Margin
5.9%
YoY Growth
16.5%
EPS
$0.27
COLLEGIUM PHARMACEUTICAL, INC Q3 FY2024 Financial Summary
COLLEGIUM PHARMACEUTICAL, INC reported revenue of $159.3M (up 16.5% YoY) for Q3 FY2024, with a net profit of $9.3M (down 54.8% YoY) (5.9% margin). Cost of goods sold was $62.5M, operating expenses totaled $62.0M.
Key Financial Metrics
| Total Revenue | $159.3M |
|---|---|
| Net Profit | $9.3M |
| Gross Margin | 60.8% |
| Operating Margin | 21.9% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
COLLEGIUM PHARMACEUTICAL, INC Q3 FY2024 revenue of $159.3M breaks down across 6 segments, led by Belbuca at $53.2M (33.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Belbuca | $53.2M | 33.4% |
| Xtampza | $49.5M | 31.1% |
| Nucynta Ir | $25.4M | 15.9% |
| Nucynta Er | $19.8M | 12.4% |
| Ironshore Acquisition | $8.0M | 5.0% |
| Symproic | $3.5M | 2.2% |
COLLEGIUM PHARMACEUTICAL, INC Revenue by Segment — Quarterly Trend
COLLEGIUM PHARMACEUTICAL, INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Belbuca and Xtampza) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Belbuca | — | $58.3M | — | $51.7M |
| Xtampza | — | $50.5M | — | — |
| Nucynta Ir | — | $32.0M | — | $27.4M |
| Nucynta Er | — | $22.8M | — | — |
COLLEGIUM PHARMACEUTICAL, INC Annual Revenue by Year
COLLEGIUM PHARMACEUTICAL, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $780.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $780.6M |
| 2024 | $631.4M |
| 2023 | $566.8M |
| 2022 | $463.9M |
COLLEGIUM PHARMACEUTICAL, INC Quarterly Revenue & Net Profit History
COLLEGIUM PHARMACEUTICAL, INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $205.4M | +12.9% | $17.0M | 8.3% |
| Q3 FY2025 | $209.4M | +31.4% | $31.5M | 15.0% |
| Q2 FY2025 | $188.0M | +29.4% | $12.0M | 6.4% |
| Q1 FY2025 | $177.8M | +22.7% | $2.4M | 1.4% |
| Q4 FY2024 | $181.9M | +21.5% | $12.5M | 6.9% |
| Q3 FY2024 | $159.3M | +16.5% | $9.3M | 5.9% |
| Q2 FY2024 | $145.3M | +7.2% | $19.6M | 13.5% |
| Q1 FY2024 | $144.9M | +0.1% | $27.7M | 19.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $144.9M | $145.3M | $159.3M | $181.9M | $177.8M | $188.0M | $209.4M | $205.4M |
| YoY Growth | 0.1% | 7.2% | 16.5% | 21.5% | 22.7% | 29.4% | 31.4% | 12.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.11B | $1.05B | $1.64B | $1.66B | $1.63B | $1.59B | $1.61B | $1.66B |
| Liabilities | $892.1M | $836.8M | $1.40B | $1.43B | $1.40B | $1.36B | $1.33B | $1.36B |
| Equity | $222.2M | $216.6M | $234.3M | $228.8M | $234.4M | $232.2M | $274.8M | $301.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $61.9M | $67.4M | $-9.0M | $84.6M | $55.4M | $72.4M | $78.4M | $123.0M |